Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Illumina edges toward drug discovery

by Jessica Marshall
May 14, 2022 | A version of this story appeared in Volume 100, Issue 17

Illumina is taking steps in the direction of drug discovery. It will partner for 5 years with the life sciences investment firm Deerfield Management. Illumina’s gene-sequencing technology and artificial intelligence tools will speed identification of drug targets, the company says, while Deerfield will bring expertise in early-stage drug development. Illumina will apply similar tools in a separate agreement with Janssen Biotech. Joydeep Goswami, Illumina’s chief strategy and corporate development officer, told a recent conference that he hopes to sign more such deals.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.